From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

Treatment of Acute Hepatitis C Appears to Be Highly Effective

In patients with long-standing hepatitis C virus (HCV) infections, even the best antiviral regimens eliminate virus only about half the time. In this industry-sponsored study from Germany, researchers sought to determine whether initiating treatment very early in the clinical course can prevent progression to chronic infection.

The study included 44 patients who presumably had acquired HCV within the previous 4 months, based on criteria such as exposure to a known source or documented seroconversion. All had detectable serum HCV RNA and elevated alanine aminotransferase (ALT) levels. They received interferon alfa-2b (5 million units daily for 4 weeks and then 3 times weekly for 20 weeks) and were followed for an additional 24 weeks after therapy ended. Of 43 patients who completed follow-up, 42 had undetectable HCV RNA and normal ALT levels. Only 1 patient discontinued treatment because of adverse effects.

Comment: These results are remarkable, but caveats are in order. First, there was no control group; however, results from other studies suggest that more than half of patients with acute hepatitis C infections develop chronic infections. Second, post-therapy follow-up was limited to 24 weeks; but, according to studies of patients treated for chronic HCV infections, absence of HCV RNA at this juncture usually indicates a durable response. And third, because patients with acute HCV infections can be asymptomatic, they often are not identified.

— AS Brett

Published in Journal Watch General Medicine October 23, 2001

Citation(s):

Jaeckel E et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001 Nov 15 345 1452-1457.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2001. Massachusetts Medical Society. All rights reserved.